Histamine Pharmacogenetics in Children With Atopic Dermatitis

Dermatitis, Atopic Clinical Trial

Official title: Histamine Pharmacogenetics in Children With Atopic Dermatitis

Status Completed

Clinical Trial Summary

The primary goal of the study is to investigate the impact of a common genetic polymorphism in a histamine detoxification enzyme that may well have a common role in regulating the expression of atopic dermatitis (AD) and other related atopic diseases in children.

Clinical Trial Description

Atopic dermatitis (AD) is a common condition in the pediatric population, affecting an estimated 15% of all children greater than 18 months of age in the United States. It is now recognized that AD is a disease of significant heterogeneity with respect to both disease severity and response to conventional pharmacologic therapies. With the recognition of this variability comes the understanding that, as with many other allergic disease, there exist many specific disease phenotypes that ultimately govern response to pharmacologic intervention. The characterization of these unique phenotypes and their associated biologic mediators is therefore of critical therapeutic importance in the development of disease and patient-specific treatment strategies.

The long term objective of this research is to explore the effects of genetic, environmental and developmental influences on the primary determinants of histamine action in atopic children and to identify potential histamine "haplotypes" that may be predictive of disease severity, progression and/or response to therapy.

The primary hypothesis is the presence of HNMT T314 allele and /or slow acetylation genotype is associated with childhood atopic dermatitis. ;

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic
• Eczema

• NCT number: NCT00277433
• Study type: Observational
• Source: Virginia Commonwealth University
• Status: Completed
• Phase: N/A
• Start date: June 2004
• Completion date: December 2009